Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor
Open Access
- 15 August 2006
- journal article
- Published by American Society of Hematology in Blood
- Vol. 108 (4) , 1174-1182
- https://doi.org/10.1182/blood-2005-09-008086
Abstract
We studied the cellular and molecular effects of the combination of an anthracycline with 2 different histone deacetylase inhibitors (HDACIs): vorinoKeywords
This publication has 27 references indexed in Scilit:
- Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced CancerJournal of Clinical Oncology, 2005
- Histone Deacetylase Inhibitors: A Review of Their Clinical Status as Antineoplastic AgentsCancer Investigation, 2005
- A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemiaBlood, 2004
- Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acidBlood, 2004
- T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistanceBlood, 2004
- Sequence‐specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acidJournal of Cellular Biochemistry, 2004
- Enhanced Radiation-Induced Cell Killing and Prolongation of γH2AX Foci Expression by the Histone Deacetylase Inhibitor MS-275Cancer Research, 2004
- Characteristics of γ-H2AX foci at DNA double-strand breaks sitesBiochemistry and Cell Biology, 2003
- Histone deacetylases and cancer: causes and therapiesNature Reviews Cancer, 2001
- Deacetylase Activity Associates with Topoisomerase II and Is Necessary for Etoposide-induced ApoptosisPublished by Elsevier ,2001